Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Entera Bio (ENTX) EBIAT (2018 - 2025)

Entera Bio has reported EBIAT over the past 8 years, most recently at -$3.0 million for Q4 2025.

  • For the quarter ending Q4 2025, EBIAT fell 27.91% year-over-year to -$3.0 million, compared with a TTM value of -$11.4 million through Dec 2025, down 19.89%, and an annual FY2025 reading of -$11.4 million, down 19.89% over the prior year.
  • EBIAT came in at -$3.0 million for Q4 2025, up from -$3.2 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$2.0 million in Q4 2023 to a low of -$9.5 million in Q1 2021.
  • Median EBIAT over the past 5 years was -$2.8 million (2025), compared with a mean of -$3.1 million.
  • The largest YoY upside for EBIAT was 76.78% in 2021 against a maximum downside of 225.15% in 2021.
  • Over 5 years, EBIAT stood at -$4.1 million in 2021, then grew by 25.98% to -$3.0 million in 2022, then surged by 34.27% to -$2.0 million in 2023, then dropped by 18.2% to -$2.4 million in 2024, then decreased by 27.91% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's EBIAT are -$3.0 million (Q4 2025), -$3.2 million (Q3 2025), and -$2.7 million (Q2 2025).